ARHGEF17 and non-small cell lung carcinoma: Analysis of the non–small cell lung carcinoma (NSCLC) TCGA datasets (61) revealed that ARHGEF17 amplification correlated with a higher percentage of patients with tumors at stages II–IV and N1–2, indicative of advanced tumor growth and lymph node infiltration, respectively (https://www.cbioportal.org/; Fig. 1, A and B; ARHGEF17 is named GEF17 in all the figures).